Book Calls For Re-Casting Debate Over TRIPS And Medicines Access

Print This Post Print This Post

A recent book analyses the role of intellectual property protection in providing incentives for innovation and its impact on access to medicines by retracing the origins, content and interpretations of the World Trade Organization agreement on IP rights and trade. It concludes that the debate needs to be recast in order for all sides to benefit going forward.

“Interpreting TRIPS: Globalisation of Intellectual Property Rights and Access to Medicines,” was written by Hiroko Yamane, professor of international economic law, competition and intellectual property at the National Graduate Institute for Policy Studies in Tokyo. She was a former negotiator on IP, innovation and public health in Geneva.

The book gives an issue-by-issue analysis of provisions of the WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and latest debates, ranging from biotechnology and patentable subject matter, to the Doha Declaration on TRIPS and Public Health, to TRIPs-plus provisions in US free trade agreements, to the use of flexibilities within the agreement. But it also examines ways to interpret TRIPS, and TRIPS and innovation, as well as policies of emerging economies and industry.

According to the publishers: “The book examines various views of the role of IPRs as incentives for innovation against the backdrop of development and the transfer of technology between globalised, knowledge-based, high technology economies. The author concludes … [that] IPR protection should be supporting domestic policies for innovation and investment. This, in turn requires a re-casting of the debate about TRIPS, to place cooperation in global and efficient R&D at the heart of concerns over IPR protection.”

The book is available from Hart Publishing, here.

Attribution-Noncommercial-No Derivative Works 3.0 Unported

Leave a Reply